Home » News » AIM News » Evgen Pharma plc Poster presentation of SFX-01 and clinical trial update
Evgen Pharma Plc

Evgen Pharma plc Poster presentation of SFX-01 and clinical trial update

Evgen Pharma plc (LON: EVG), a clinical stage drug development company focused on the treatment of cancer and neurological conditions, announced today that a trials-in-progress poster of the Company’s Phase II trial of SFX-01 in metastatic breast cancer will be presented this week at the San Antonio Breast Cancer Symposium 2018 in San Antonio, Texas.

The poster, entitled STEM: SFX-01 in the Treatment and Evaluation of Metastatic Breast Cancer, will be presented in a poster session on Wednesday 5 December 2018. The poster gives the background to SFX-01 along with a description of the STEM trial including its primary and second endpoints.

After a positive interim readout, recruitment in the STEM trial concluded in July this year. The final patient on the trial will take her last dose of SFX-01 before the end of December 2018, meaning that the final readout of the trial is expected in February or March 2019.

The San Antonio Breast Cancer Symposium is on 4-8 December 2018 in San Antonio, Texas, at the Henry B. Gonzalez Convention Center. Further information is available at this link: www.sabcs.org.

A copy of the Evgen Pharma poster will be made available on the Company’s website, www.evgen.com, following its presentation at the San Antonio symposium.